← Back to Search

Fluorescent Dye

NIR Fluorescence-Guided Surgery for Early Stage Lung Cancer

Phase 1
Recruiting
Led By Waël C. Hanna, MDCM, MBA, FRCSC
Research Sponsored by St. Joseph's Healthcare Hamilton
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
CT-imaging confirming that the tumour is confined to the one broncho-pulmonary segment, rendering the patient a candidate for segmental resection.
Tumor size <3 cm
Must not have
Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing a new way to do a surgery called a segmentectomy. Segmentectomy is hard to do robotically because it is difficult to view the tissue lines that separate each segment within the lobe. The new method uses Near-Infrared Fluorescence (NIF) to make it easier to see which pieces of tissue should be removed.

Who is the study for?
This trial is for adults over 18 with early-stage non-small cell lung cancer (NSCLC), specifically Clinical Stage 1, where the tumor is less than 3 cm and confined to a single segment of the lung. It's not suitable for those allergic to indocyanine green or iodine, nor for pregnant or breastfeeding women without effective birth control.
What is being tested?
The study tests a surgical technique called Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy using indocyanine green dye. This aims to help surgeons remove only the affected lung segment instead of an entire lobe, preserving more healthy tissue in patients with small tumors.
What are the potential side effects?
Potential side effects may include reactions related to indocyanine green such as allergy symptoms. Surgical risks involve complications from anesthesia, bleeding, infection, and possibly extended surgery if complete tumor removal isn't achieved initially.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My CT scan shows my lung tumor is in one segment, making me eligible for a specific type of surgery.
Select...
My tumor is smaller than 3 cm.
Select...
My condition is stage 1 non-small cell lung cancer.
Select...
I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant, breastfeeding, or able to become pregnant without using birth control.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Malignant Neoplasms
Secondary study objectives
Added value of ICG-guidance will be evaluated using Item 7 of the 7-item binary rating scale. A score of 1/7 will indicate added value of ICG-guidance
Anatomical accuracy will be evaluated using items 4, 5, and 6 of the Indocyanine Green Segmentectomy 7-Item Binary Scale. A score of 3/7 on these items will indicate success of anatomical accuracy
Learning Curve

Side effects data

From 2016 Phase 3 trial • 99 Patients • NCT02279108
22%
lymphocele
10%
hematoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Double Detection Indocyanine + Isotope
Isotope Detection Alone

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: indocyanine greenExperimental Treatment1 Intervention
Non-toxic, fluorescent dye
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indocyanine green
FDA approved

Find a Location

Who is running the clinical trial?

St. Joseph's Healthcare HamiltonLead Sponsor
201 Previous Clinical Trials
26,703 Total Patients Enrolled
Waël C. Hanna, MDCM, MBA, FRCSCPrincipal InvestigatorSt. Joseph's Healthcare Hamilton / McMaster University
1 Previous Clinical Trials

Media Library

Indocyanine Green (Fluorescent Dye) Clinical Trial Eligibility Overview. Trial Name: NCT02570815 — Phase 1
Lung Cancer Research Study Groups: indocyanine green
Lung Cancer Clinical Trial 2023: Indocyanine Green Highlights & Side Effects. Trial Name: NCT02570815 — Phase 1
Indocyanine Green (Fluorescent Dye) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02570815 — Phase 1
~28 spots leftby Nov 2025